51 related articles for article (PubMed ID: 11899646)
1. Tumor reductive therapies and antitumor immunity.
Guo H; Tsung K
Oncotarget; 2017 Aug; 8(33):55736-55749. PubMed ID: 28903456
[TBL] [Abstract][Full Text] [Related]
2. Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer.
Pinzon-Charry A; Ho CS; Maxwell T; McGuckin MA; Schmidt C; Furnival C; Pyke CM; López JA
Br J Cancer; 2007 Nov; 97(9):1251-9. PubMed ID: 17923873
[TBL] [Abstract][Full Text] [Related]
3. Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients.
Croce MV; Isla-Larrain M; Tur R; Rabassa ME; Segal-Eiras A
Clin Exp Metastasis; 2004; 21(2):139-47. PubMed ID: 15168731
[TBL] [Abstract][Full Text] [Related]
4. Rating of isolated disseminated tumor cells in bone marrow in comparison with other factors of prognosis in breast carcinoma.
Leinung S; Würl P; Schönfelder A; Weiss CL; Röder I; Schönfelder M
Int J Surg Investig; 2000; 2(3):193-202. PubMed ID: 12678519
[TBL] [Abstract][Full Text] [Related]
5. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.
Braun S; Schlimok G; Heumos I; Schaller G; Riethdorf L; Riethmüller G; Pantel K
Cancer Res; 2001 Mar; 61(5):1890-5. PubMed ID: 11280743
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity.
Müller V; Stahmann N; Riethdorf S; Rau T; Zabel T; Goetz A; Jänicke F; Pantel K
Clin Cancer Res; 2005 May; 11(10):3678-85. PubMed ID: 15897564
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of occult metastatic cells in the bone marrow of patients with different stages of breast cancer.
Janni W; Rjosk D; Braun S
Clin Breast Cancer; 2000 Oct; 1(3):217-25. PubMed ID: 11899646
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of occult metastatic tumor cells in bone marrow.
Pantel K; Braun S
Clin Breast Cancer; 2001 Oct; 2(3):222-8. PubMed ID: 11899416
[TBL] [Abstract][Full Text] [Related]
9. BM micrometastases and circulating tumor cells in breast cancer patients: where have we been, where are we now and where does the future lie?
Müller V; Pantel K
Cytotherapy; 2005; 7(6):478-82. PubMed ID: 16306009
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.
Diel IJ; Cote RJ
Cancer Treat Rev; 2000 Feb; 26(1):53-65. PubMed ID: 10660491
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
